Innovent Biologics says Q3 2026 product revenue topped RMB4.7 billion
Innovent Biologics said its product revenue for the third quarter of 2026 exceeded RMB4.7 billion, up more than 40% year over year, per Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Chinese biotech company Innovent Biologics said its product revenue in the third quarter of 2026 came in above RMB4.7 billion. That is more than 40% higher than a year earlier.
The information was published by Reuters, citing the company's own statement.
why it matters
For the broader market this is an operating update from a single company, so its wider impact is limited. Biotech investors typically track sales growth figures like these to gauge how well a drugmaker's products are selling.
tags
instruments
sources
- Innovent Biologics Says Q3 2026 Product Revenue Exceeds RMB4.7 Bln — Reuters, 29 October 2026 at 01:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗